Cell Therapeutics (CTIC)

Must be logged in to add this company to your watchlist.

Click here to login.

CTIC - NASDAQ - 3/16/2010 5:36 PM

1.06
Change 0.05
% Change 4.95%
Market Cap Revenue Growth Profit Margin Cash
$592.87M -99.22% -136900% $37.81M
2061 / 4588 4528 / 4575 4573 / 4574 2521 / 4125

For the December 2009 quarter, Cell Therapeutics spent 36500% of gross profits on R&D and 94750% on SGA expenses. Revenues fell 99.22% year-over-year to $0.02M. The company is trading at an unknown amount times earnings(PE) and 7410.88 times revenue(PSR). At the end of December 2009, Cell Therapeutics had $37.81M in cash on hand and $1.86M in long-term debt. On 02/11/2010, Cell Therapeutics reported net loss of $27.38M, with diluted earnings per share of $-0.05.

Valuation

Add More Charts

Price

Current stock price.

PE Ratio

Price paid for a share relative to the annual income earned.

Price to Sales Ratio: 7410.88

Market cap divided by revenue.

Growth & Profitability

Add More Charts

Revenue Growth: -99.22%

Revenue growth year-over-year.

Earnings per Share: $-0.05

Portion of profit allocated to each outstanding share of common stock.

Profit Margin: -136900%

Margin made on every dollar of revenue.

Fundamentals

Add More Charts

Income Statement

Summary of revenues, expenses & profits.

Balance Sheet

Company's assets, liabilities & shareholders' equity at a specific point in time.

Cash Flow

Cash inflows arise from one of three activities - operations, financing, or investing.